Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age20+
SponsorTaichung Veterans General Hospital
About this trial
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Eligibility criteria
Qualifiers
Patients more than 20 years old
Chronic hepatitis B patients
Patients who were indicated for hepatitis B virus antiviral therapy
Disqualifiers
Decompensated liver disease (Child-Pugh B &C)
End stage renal disease (eGRF < 15 ml/min/1.73m2)
Prior use of nucleot(s)ide analogues for chronic hepatitis B
Prior use of interferon for chronic hepatitis B within six months
Trial design
Treatments tested in this trial
- Tenofovir alafenamide
- Entecavir
Treatment groups
140 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov